Wish i was in Europe.
A
StemCells, Inc. Receives Authorization to Conduct World's First
Neural Stem Cell Trial in Spinal Cord Injury
PALO ALTO, Calif., Dec 7, 2010 (GlobeNewswire via COMTEX) --
StemCells, Inc. (Nasdaq:STEM) announced today that is has received
authorization from Swissmedic, the Swiss regulatory agency for
therapeutic products, to initiate a Phase I/II clinical trial in
Switzerland of the Company's proprietary HuCNS-SC(R) product
candidate (purified human neural stem cells) in chronic spinal cord
injury. The trial is designed to assess both safety and preliminary
efficacy in patients with varying degrees of paralysis who are three
to 12 months post-injury, and will progressively enroll patients
based upon the severity of injury. Enrollment is expected to begin
in early 2011.
--
